Location History:
- Saitama, JP (2013 - 2018)
- Tokyo, JP (2015 - 2024)
Company Filing History:
11 out of 441 
2 out of 79 
1 out of 14 Years Active: 2013-2025
Title: Toshiaki Ohtsuka: Innovator in Antibody Development
Introduction
Toshiaki Ohtsuka is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of innovative antibodies. With a total of 11 patents to his name, Ohtsuka has established himself as a key figure in the fight against tumors.
Latest Patents
One of Ohtsuka's latest patents involves a bispecific antibody that serves as an anti-tumor agent. This antibody comprises a molecule that includes specific heavy and light chain CDR sequences, which are crucial for its binding capabilities. The detailed composition of the antibody includes a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, and a heavy chain CDRH3 consisting of SEQ ID NO: 56. Additionally, the light chain CDRL1 consists of SEQ ID NO: 57 or a variant thereof, while the light chain CDRL2 and CDRL3 consist of SEQ ID NO: 58 and SEQ ID NO: 59, respectively. This innovative approach has the potential to enhance therapeutic options for cancer treatment.
Career Highlights
Throughout his career, Ohtsuka has worked with notable organizations, including Daiichi Sankyo Company, Limited and Mie University. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Ohtsuka has collaborated with esteemed colleagues such as Toshinori Agatsuma and Tatsuji Matsuoka. These partnerships have fostered an environment of innovation and have led to significant advancements in antibody research.
Conclusion
Toshiaki Ohtsuka's work in the development of bispecific antibodies marks a significant advancement in cancer treatment. His contributions to biotechnology continue to inspire future innovations in the field.